GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halberd Corp (OTCPK:HALB) » Definitions » Revenue

Halberd (Halberd) Revenue : $ Mil (TTM As of Jul. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Halberd Revenue?

Halberd's revenue for the six months ended in Jul. 2023 was $0.00 Mil. Halberd does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Jul. 2023. Halberd's Revenue per Share for the six months ended in Jul. 2023 was $0.00. Halberd does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Jul. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Halberd Revenue Historical Data

The historical data trend for Halberd's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halberd Revenue Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Revenue
0.01 0.01 -

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Revenue 0.01 0.01 -

Competitive Comparison of Halberd's Revenue

For the Biotechnology subindustry, Halberd's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Halberd's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halberd's Revenue distribution charts can be found below:

* The bar in red indicates where Halberd's Revenue falls into.



Halberd Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.


Halberd  (OTCPK:HALB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Halberd Revenue Related Terms

Thank you for viewing the detailed overview of Halberd's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Halberd (Halberd) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a research-based biotechnology company seeking to discover and develop medical treatments for a range of diseases. The Company's extracorporeal treatment is designed to treat hard-to-cure blood-borne, neurologic and infectious diseases. The Company's patented methodology removes the appropriate bodily fluid from the patient, in a continuous fashion, like dialysis, or in a batch process, like blood sample testing.
Executives
John Christopher Maddox director, 10 percent owner, officer: President, COO, Treasurer and, other: Interim CFO 10755 VERNON, HUNTINGTON WOODS MI 48070
Mark Sven Lundquist director, 10 percent owner, officer: CEO, Secretary and Director 24655 TUDOR LANE, FRANKLIN MI 48025
Cocco Nicholas A. Jr. director 50104 N. JIMMY COURT, CHESTERFIELD MI 48047-1898
Leland Michael Thomas director 280 LASALLE PLACE, GROSSE POINTE FARMS MI 88236